| Literature DB >> 31680887 |
Jie Chen1, Li Zhang1, Lanying Liu2, Xueqin Yang3, Fengzhi Wu4, Xiulun Gan3, Rong Zhang1, Yinjia He1, Qiuyi Lv1, Haonan Fu1, Ling Zhou1, Jiaxi Zhang1, Anming Liu1, Xiaodong Liu1, Linqing Miao5.
Abstract
Glaucoma and traumatic optic nerve crush (ONC) injury result in progressive loss of retinal ganglion cells (RGCs) and defects in visual function. In clinical trials of Traditional Chinese Medicine, acupuncture has been widely used for the treatment of ocular diseases. However, the molecular mechanisms of acupuncture treatment are still unclear. In this study, we used technique of RNA sequencing (RNA-seq) to study the effects of acupuncture treatment on retinal transcriptome after axotomy injury. RNA-seq results revealed that 436 genes including 31 transcription factors (TFs) were changed after injury, among them were many well-known neural degeneration related TFs such as Jun, Ddit3, Atf3, and Atf4. Interestingly, acupuncture treatment at acupoint GB20 (Fengchi) significantly reversed a series of differential expressed genes (DEGs) induced by optic nerve injury. While treatments at BL1 (Jingming) or GB20 sham control acupoint-GV16 (Fengfu), led to limited DEG reversal. In contrast, treatments at these two sites further enhanced the trend of DEG expression induced by axotomy injury. At last, retina immunostaining results revealed that only GB20 acupoint treatment increased RGC survival, in consistent with RNA-seq results. Therefore, our study first reported that acupuncture treatment regulated retinal transcriptome and reversed the gene expression induced by axotomy injury, and GB20 acupoint treatment increased RGC survival, which will provide novel therapeutic targets for treatment of ocular diseases.Entities:
Keywords: BL1 (Jingming); GB20 (Fengchi); GV16 (Fengfu); RNA sequencing; acupuncture; optic nerve crush; retinal ganglion cells; transcriptome
Year: 2019 PMID: 31680887 PMCID: PMC6808026 DOI: 10.3389/fnint.2019.00059
Source DB: PubMed Journal: Front Integr Neurosci ISSN: 1662-5145
FIGURE 1The acupoints for acupuncture treatments. (A) Photos of mice showing the sites of acupuncture treatments at acupoints BL1, GB20, and GV16, respectively. (B) Schematic image demonstrating acupoint sites on mouse.
FIGURE 2Quantitative analysis of retinal gene expression. (A) Boxplot shows the overall range and distribution of FPKM value of gene expression of all the samples. (B) PCA analysis shows the differentiation among samples. (C) Cluster analysis of differentially expressed genes among samples and groups. The color of the heat map indicated the relative gene expression. The deeper red color indicates the higher gene expression, while the deeper blue color indicates the lower gene expression.
FIGURE 3Differentially expressed genes induced by ONC injury. (A) The volcano map shows the overall differentially expressed genes after ONC injury, compared with WT control. (B) Enriched gene ontology analysis of up-regulated DEGs. (C) Enriched gene ontology analysis of down-regulated DEGs. padj: adjusted p value.
Top 20 upregulated and 20 downregulated genes induced by ONC injury.
| Sprr1a | 10.2 | 3.6E-15 | ENSMUSG00000050359 | Small proline-rich protein 1A [Source:MGI Symbol;Acc:MGI:106660] |
| Gm29374 | 7.3 | 5.3E-07 | ENSMUSG00000099839 | Predicted gene 29374 [Source:MGI Symbol;Acc:MGI:5580080] |
| Gm38403 | 6.8 | 4.1E-05 | ENSMUSG00000112854 | Predicted gene, 38403 [Source:MGI Symbol;Acc:MGL:5621288] |
| Ecel1 | 6.7 | 3.8E-84 | ENSMUSG00000026247 | Endothelin converting enzyme-like 1 [Source:MGI Symbol;Acc:MGI:1343461] |
| Mmp12 | 6.2 | 1.3E-49 | ENSMUSG00000049723 | Matrix metallopeptidase 12 [Source:MGI Symbol;Acc:MGI:97005] |
| Cox6a2 | 4.9 | 4.0E-05 | ENSMUSG00000030785 | Cytochromec oxidase subunit 6A2 [Source:MGI Symbol;Acc:MGI:104649] |
| Cyb5r2 | 3.8 | 1.4E-05 | ENSMUSG00000048065 | Cytochromeb5 reductase 2 [Source:MGI Symbol;Acc:MGI:2444415] |
| Tmc1 | 3.8 | 1.8E-05 | ENSMUSG00000024749 | Transmembrane channel-like gene family 1 [Source:MGI Symbol;Acc:MGI:2151016] |
| Chac1 | 3.3 | 1.9E-51 | ENSMUSG00000027313 | ChaC, cation transport regulator 1 [Source:MGI Symbol;Acc:MGI:1916315] |
| Gm47593 | 3.1 | 2.5E-04 | ENSMUSG00000112058 | Predicted gene, 47593 [Source:MGI Symbol;Acc:MGI:6096640] |
| AC167169.1 | 3.0 | 1.6E-06 | ENSMUSG00000117324 | Novel transcript, antisense to Dscam |
| Plaur | 3.0 | 3.2E-02 | ENSMUSG00000046223 | Plasmnogen activator urokinase receptor [Source:MGI Symbol;Acc:MGI:97612] |
| Top2a | 2.8 | 4.0E-02 | ENSMUSG00000020914 | Topoisomerase (DNA) II alpha [Source:MGI Symbol;Acc:MGI:98790] |
| Hmox1 | 2.8 | 2.8E-02 | ENSMUSG00000005413 | Heme oxygenase 1 [Source:MGI Symbol;Acc:MGI:96163] |
| Atf3 | 2.8 | 1.0E-67 | ENSMUSG00000026628 | Activating transcription factor3 [Source:MGI Symbol;Acc:MGI:109384] |
| Hrk | 2.7 | 8.2E-40 | ENSMUSG00000046607 | Harakiri, BCL2 interacting protein (contains only BH3 domain) [Source:MGI Symbol;Acc:MGI:1201608] |
| Sox11 | 2.7 | 2.0E-48 | ENSMUSG00000063632 | SRY (sex determining region Y)-box 11 [Source MGI Symbol;Acc:MGI:98359] |
| Cdkn1a | 2.6 | 1.3E-24 | ENSMUSG00000023067 | Cyclin-dependent kinase inhibitor 1A (P21) [Source:MGI Symbol;Acc:MGI:104556] |
| Lad1 | 2.4 | 3.6E-02 | ENSMUSG00000041782 | Ladinin [Source:MGI Symbol;Acc:MGI:109343] |
| Tnfrsf12a | 2.4 | 2.7E-66 | ENSMUSG00000023905 | Tumor necrosis factor receptor superfamily, member 12a [Source:MGI Symbol:Acc:MGI:1351484] |
| Scn4b | –3.38 | 4.1E-23 | ENSMUSG00000046480 | Sodium channel type IV beta [Source MGI Symbol;Acc:MGI:2687406] |
| Ppp1r1c | –3.10 | 1.2E-03 | ENSMUSG00000034683 | Protein phosphatase 1, regulatory inhibitor subunit 1C [Source:MGI Symbol;Acc:MGI:1923185] |
| Irx4 | –2.36 | 1.0E-14 | ENSMUSG00000021604 | Iroguois homeobox 4 [Source:MGI Symbol;Acc:MGI:1355275] |
| Gpr101 | –2.20 | 2.4E-02 | ENSMUSG00000036357 | G protein-coupled receptor 101 [Source MGI Symbol;Acc:MGI:2685211] |
| Hapln1 | –2.16 | 5.7E-04 | ENSMUSG00000021613 | Hyaluronan and proteoglycan link protein 1 [Source:MGI Symbol;Acc:MGI:1337006] |
| Efcab1 | –1.94 | 1.2E-02 | ENSMUSG0C0O0068617 | EF-hand calcium binding domain 1 [Source:MGI Symbol;Acc:MGI:1914043] |
| Pou4f2 | –1.88 | 1.6E-20 | ENSMUSG00000031688 | POU domain, class 4, transcnption factor 2 [Source:MGI Symbol;Acc:MGI:102524] |
| Htr1b | –1.86 | 1.0E-14 | ENSMUSG00000049511 | 5-hydroxytryptamine (serotonin) receptor IB [Source:MGI Symbol;Acc:MGI:96274] |
| Ctxn3 | –1.82 | 6.2E-11 | ENSMUSG00000069372 | Cortexin 3 [Source:MGI Symbol;Acc:MGI:3642816] |
| Kctd19 | –1.75 | 1.6E-03 | ENSMUSG00000051648 | Potassium channel tetramerization domain containing 19 [Source:MGI Symbol;Acc:MGI:3045294] |
| D130079A08Rik | –1.72 | 2.5E-02 | ENSMUSG00000115424 | RIKEN cDNA D130079A08 gene [Source:MGI Symbol;Acc:MGI:2444500] |
| Tusc5 | –1.65 | 4.7E-38 | ENSMUSG00000046275 | Tumor suppressor candidate 5 [Source:MGI Symbol;Acc:MGI:3029307] |
| Pvalb | –1.61 | 9.8E-12 | ENSMUSG00000005716 | Parvalbumin [Source:MGI Symbol;Acc:MGI:97821] |
| 2600014E21Rik | –1.52 | 4.2E-02 | ENSMUSG00000100303 | RIKEN cDNA 2600014E21 gene [Source:MGI Symbol;Acc:MGI:1919384] |
| Irx2 | –1.51 | 6.3E-05 | EMSMUSG00000001504 | Iroguois homeobox2 [Source:MGI Symbol;Acc:MGI:1197526] |
| Tbx20 | –1.48 | 1.0E-02 | ENSMUSG00000031965 | T-box 20 [Source:MGI Symbol;Acc:MGI:1888496] |
| Isl2 | –1.47 | 4.0E-08 | ENSMUSG00000032318 | Insulin related protein 2 (islet 2) [Source:MGI Symbol;Acc:MGI:109156] |
| Tppp3 | –1.45 | 1.1E-35 | ENSMUSG00000014846 | Tubulin polymerization-promoting protein family member3 [Source:MGI Symbol;Acc:MGI:1915221] |
| Sncg | –1.43 | 9.8E-66 | ENSMUSG00000023064 | Synuclein, gamma [Source:MGI Symbol;Acc:MGI:1298397] |
| Hydin | –1.40 | 3.4E-02 | ENSMUSG00000059854 | HYDIN, axonemal central pair apparatus protein [Source:MGI Symbol;Acc:MGI:2389007] |
Transcription factors regulated by ONC injury.
| Atf3 | 2.75 | 1.02E-67 | ENSMUSG00000026628 | Activating transcription factor3 [Source:MGI Symbol;Acc:MGI:109384] |
| Sox11 | 2.68 | 2.05E-48 | ENSMUSG00000063632 | SRY (sex determining region Y]-box 11 [Source:MGI Symbol;Acc:MGI:98359] |
| Arid5a | 1.45 | 8.81E-29 | ENSMUSG00000037447 | AT rich interactive domain 5A (MRFl-like) [Source:MGI Symbol;Acc:MGI:2443039] |
| Egr3 | 1.29 | 1.58E-02 | ENSMUSG00000033730 | Early growth response3 [Source:MGI Symbol;Acc:MGI:1306780] |
| Atf5 | 1.19 | 1.99E-28 | ENSMUSG00000038539 | Activating transcription factor 5 [Source:MGI Symbol;Acc:MGI:2141857] |
| Creb5 | 1.17 | 2.48E-04 | ENSMUSG00000053007 | cAMP responsive element binding protein 5 [Source:MGI Symbol;Acc:MGI:2443973] |
| Cebpb | 1.13 | 1.79E-03 | ENSMUSG00000056501 | CCAAT/enhancer binding protien (C/EBP), beta [Source [731 Symbo;Acc:MGI:88373] |
| Ddit3 | 0.87 | 9.19E-28 | ENSMUSG00000025408 | DNA-damage inducible transcript 3 [Source:MGI Symbol;Acc:MGI:109247] |
| Fosl2 | 0.65 | 7.05E-05 | ENSMUSG00000029135 | Fos-like antigen 2 [Source:MGI Symbol;Acc:MGI:102858] |
| Jun | 0.46 | 3.36E-13 | ENSMUSG00000052684 | Jun proto-oncogene [Source:MGI Symbol;Acc:MGI:96646] |
| Klf6 | 0.46 | 5.76E-03 | ENSMUSG00000000078 | Kruppel-like factor 6 [Source:MGI Symbol;Acc:MGI:1346318] |
| Bcl6 | 0.46 | 3.35E-02 | ENSMUSG00000022508 | B cell leukemia/lymphoma 6 [Source:MGI Symbol;Acc:MGI:107187] |
| Tead3 | 0.38 | 1.20E-02 | ENSMUSG00000002249 | TEA domain family member 3 [Source:MGI Symbol;Acc:MGI:109241] |
| Bhlhe40 | 0.31 | 1.19E-02 | ENSMUSG00000030103 | Basic helix-loop-helix family, member e40 [Source:MGI Symbol;Acc:MGI:1097714] |
| Atf4 | 0.19 | 4.73E-02 | ENSMUSG00000042406 | Activating transcription factor 4 [Source:MGI Symbol;Acc:MGI:88096] |
| Tsc22d1 | –0.19 | 1.32E-02 | ENSMUSG00000022010 | TSC22 domain family, member l [Source:MGI Symbol;Acc:MGL:109127] |
| Six3 | –0.24 | 1.18E-02 | ENSMUSG00000038805 | Sine oculis-related homeobox 3 [Source:MGI Symbol;Acc:MGI:102764] |
| Sebox | –0.25 | 4.97E-02 | ENSMUSG00000001103 | SEBOX homeobox [Source:MGI Symbol;Acc:MGI:108012] |
| Myt1I | –0.26 | 3.18E-02 | ENSMUSG00000061911 | Myelin transcription factor 1ike [Source:MGI:Symbol;Acc:MGI:1100511] |
| Ebf1 | –0.38 | 2.29E-02 | ENSMUSG00000057098 | Early B cell factor 1 [Source:MGI Symbol;Acc:MGI:95275] |
| Scrt1 | –0.41 | 1.50E-07 | ENSMUSG00000048385 | Scratch family zinc finger 1 [SourceMGI Symbol:Acc:MGL:2176606] |
| Irx6 | –0.56 | 3.33E-03 | ENSMUSG00000031738 | Iroguois homeobox 6 [Source:MGI Symbol;Acc:MGI:1927642] |
| Eomes | –0.67 | 1.58E-02 | ENSMUSG00000032446 | Eomesodermin [Source:MGI Symbol;Acc:MGI:1201683] |
| Zicl | –0.70 | 2.12E-02 | ENSMUSG00000032368 | Zinc finger protein of the cerebellum 1 [Source:MGI Symbol;Acc:MGI:106683] |
| Pou6f2 | –0.84 | 3.05E-04 | ENSMUSG00000009734 | POU domain, class 6, transcriptionfactor 2 [Source:MGI Symbol;Acc:MGI:2443631] |
| Pou4f1 | –0.92 | 2.79E-16 | ENSMUSG00000048349 | POU domain, class4, transcription factor 1 [Source:MGI Symbol;Acc:MGI:102525] |
| IsI2 | –1.47 | 4.00E-08 | ENSMUSG00000032318 | Insulin related protein 2 (islet 2)[Source:MGI Symbol;Acc:MGI:109156] |
| Tbx20 | –1.48 | 1.02E-02 | ENSMUSG00000031965 | T-box 20 [Source:MGI Symbol;Acc:MGI:1888496] |
| Irx2 | –1.51 | 6.26E-05 | ENSMUSG00000001504 | Iroquois homeobox 2[Source:MGI Symbol;Acc:MGI:1197526] |
| Pou4f2 | –1.88 | 1.561-20 | ENSMUSG00000031688 | POU domain, class4, transcription factor 2 [Source:MGI Symbol;Acc:MGI:102524] |
| Irx4 | –2.36 | 1.02E-14 | ENSMUSG00000021604 | Iroguois homeobox 4 [Source:MGI Symbol;Acc:MGI:1355275] |
FIGURE 4Reversal of DEGs by acupuncture treatment after ONC injury. (A–C) Volcano map shows the reversal of up-regulated DEGs induced by ONC injury after acupuncture treatments at acupoint BL1, GB20, and GV16 (Sham control site). (D–F) Volcano map shows the reversal of down-regulated DEGs induced by ONC injury after acupuncture treatments at acupoint BL1, GB20, and GV16. p value < 0.05.
FIGURE 5Validation of selected TFs and DEGs with qRT-PCR. (A–D) Statistical graph shows fold change of TFs mRNA expression, normalized to GAPDH level. (E–H) Statistical graph shows fold change of mRNA expression of DEGs reversed by acupuncture treatment, normalized to GAPDH level. Data are represented as means ± SEM; n = 3; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
FIGURE 6Promotion of RGC survival by acupuncture treatment. (A) Confocal images showing the co-staining of RGC with antibodies of RBMPS (RGC specific marker) and Tuj1 (neuron specific marker). (B) Statistical analysis of survival RGC percentage relative to intact naïve retina. Data are represented as means ± SEM; n = 5; ∗∗∗p < 0.001.